Clinical Trial Update: Brentuximab Vedotin for Systemic Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update reports completion of Phase 1/2 studies evaluating Brentuximab Vedotin for diffuse cutaneous systemic sclerosis (scleroderma), with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Diffuse Cutaneous Systemic Sclerosis, Scleroderma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-17